These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15070695)

  • 1. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.
    Asosingh K; De Raeve H; Menu E; Van Riet I; Van Marck E; Van Camp B; Vanderkerken K
    Blood; 2004 Apr; 103(8):3131-7. PubMed ID: 15070695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.
    Asosingh K; De Raeve H; de Ridder M; Storme GA; Willems A; Van Riet I; Van Camp B; Vanderkerken K
    Haematologica; 2005 Jun; 90(6):810-7. PubMed ID: 15951294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.
    Asosingh K; Menu E; Van Valckenborgh E; Vande Broek I; Van Riet I; Van Camp B; Vanderkerken K
    Clin Exp Metastasis; 2002; 19(7):583-91. PubMed ID: 12498387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis.
    Asosingh K; De Raeve H; Van Riet I; Van Camp B; Vanderkerken K
    Blood; 2003 Apr; 101(8):3136-41. PubMed ID: 12480692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
    Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
    Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model.
    Asosingh K; Willems A; Van Riet I; Van Camp B; Vanderkerken K
    Cancer Res; 2003 Jun; 63(12):3019-20. PubMed ID: 12810619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis in multiple myeloma.
    Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
    Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
    Kumar S; Witzig TE; Timm M; Haug J; Wellik L; Kimlinger TK; Greipp PR; Rajkumar SV
    Blood; 2004 Aug; 104(4):1159-65. PubMed ID: 15130943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of IFN-gamma production by TNF-alpha in macrophages from the tumor environment: significance as an angiogenic switch.
    Lee H; Baek S; Joe SJ; Pyo SN
    Int Immunopharmacol; 2006 Jan; 6(1):71-8. PubMed ID: 16332515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Influence of rosiglitazone and all-trans-retinoic acid on angiogenesis and growth of myeloma xenograft in nude mice].
    Huang HW; Chen P; Li BZ; Fu JX; Li J; Zhang XH; Liu R; Fan YY; Zhang H; Chow HC; Leung AY; Liang R
    Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):652-7. PubMed ID: 23159076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells.
    Asosingh K; De Raeve H; Croucher P; Goes E; Van Riet I; Van Camp B; Vanderkerken K
    Exp Hematol; 2001 Jan; 29(1):77-84. PubMed ID: 11164108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
    Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
    Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notch1 overexpression promotes cell growth and tumor angiogenesis in myeloma.
    Guo D; Li C; Teng Q; Sun Z; Li Y; Zhang C
    Neoplasma; 2013; 60(1):33-40. PubMed ID: 23067214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of clinical prognostic value of vascular endothelial growth factor and microvessel density in multiple myeloma.
    Choi JH; Ahn MJ; Jang SJ; Park CK; Park YW; Oh HS; Lee YY; Choi IY; Kim IS
    Int J Hematol; 2002 Dec; 76(5):460-4. PubMed ID: 12512841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
    Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
    Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
    Wada H; Nagano H; Yamamoto H; Arai I; Ota H; Nakamura M; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Doki Y; Dono K; Nakamori S; Sakon M; Monden M
    Oncol Rep; 2007 Oct; 18(4):801-9. PubMed ID: 17786339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.
    Storti P; Donofrio G; Colla S; Airoldi I; Bolzoni M; Agnelli L; Abeltino M; Todoerti K; Lazzaretti M; Mancini C; Ribatti D; Bonomini S; Franceschi V; Pistoia V; Lisignoli G; Pedrazzini A; Cavicchi O; Neri A; Rizzoli V; Giuliani N
    Leukemia; 2011 Mar; 25(3):527-37. PubMed ID: 21183939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.
    Kokonozaki M; Tsirakis G; Devetzoglou M; Kyriakaki S; Antonakis A; Vyzoukaki R; Pappa CA; Tzardi M; Alexandrakis MG
    Leuk Res; 2015 Dec; 39(12):1467-72. PubMed ID: 26521986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
    Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
    J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.